Title of Collaborative Activity: |
FDA Acute Radiation Syndrome (ARS) Action Team |
Description of Collaborative Activity: |
The purpose of this collaboration is to inform members of the Food and Drug Administration (FDA) Acute Radiation Syndrome (ARS) Action Team on key data from the radiation and nuclear countermeasures program (RNCP) drug development portfolio that will inform them in advancing products that may be brought forward for eventual licensure. A biweekly meeting takes place between the National Institute of Allergy and Infectious Diseases (NIAID) (RNCP/Program Officer) and FDA(OCET/Senior Advisor) Senior Advisor to decide which medical countermeasures (MCMs) will be presented to the Action Team. |
Type of Collaborative Activity: |
Committee, Advisory Group, or Work Group
|
Year the Collaborative Activity Originated: |
2017 |
NIH Participating Institutes/Centers/Office of the Director: |
NIAID |
HHS Agency Collaborators on this Activity: |
FDA |
